P
Ping Zhan
Researcher at Nanjing University
Publications - 49
Citations - 1332
Ping Zhan is an academic researcher from Nanjing University. The author has contributed to research in topics: Lung cancer & Metastasis. The author has an hindex of 18, co-authored 49 publications receiving 791 citations. Previous affiliations of Ping Zhan include Nanjing Medical University & Southeast University.
Papers
More filters
Journal ArticleDOI
PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway.
Ping Zhan,Ping Zhan,Bin Zhang,Guang-min Xi,Ying Wu,Hongbing Liu,Yafang Liu,Wujian Xu,Qingqing Zhu,Feng Cai,Ze-Jun Zhou,Ying-ying Miu,Xiaoxia Wang,Jia-jia Jin,Qian Li,Li-ping Qian,Tangfeng Lv,Yong Song +17 more
TL;DR: This investigation offers confirmation that PRC1 is a prognostic and promising therapeutic biomarker for people with lung adenocarcinoma and takes on a key part in the activation of the Wnt/β-catenin pathway in lung adnocarc inoma development.
Journal ArticleDOI
GSDMD is required for effector CD8+ T cell responses to lung cancer cells
TL;DR: It is shown that the expression of GSDMD was consistently correlated with CD8+ T cell markers in The Cancer Genome Atlas (TCGA) cohorts and demonstrated that G SDMD is required for an optimal CTL response to cancer cells.
Journal ArticleDOI
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Yangbo Hu,Qun Zhang,Huijuan Li,Jean M. Michot,Hongbing Liu,Ping Zhan,Ping Zhan,Tangfeng Lv,Yong Song,Yong Song +9 more
TL;DR: The incidence of pneumonitis in PD-1 and PD-L1 inhibitor therapy was significantly higher than that in chemotherapy and more studies should be conducted to investigate the incidence of these rare but life-threatening IRAEs.
Journal ArticleDOI
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment.
Tianli Zhang,Bing Wan,Yuan Zhao,Chuling Li,Hongbing Liu,Hongbing Liu,Hongbing Liu,Tangfeng Lv,Tangfeng Lv,Tangfeng Lv,Ping Zhan,Ping Zhan,Ping Zhan,Yong Song,Yong Song,Yong Song +15 more
TL;DR: An overview of the clinical characteristics, incidence, and outcomes of patients harboring G719X, S768I, L861Q, exon 20 insertions, and complex mutations who were treated with TKIs, chemotherapy, or immunotherapy is provided.
Journal ArticleDOI
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
Yangyang Xu,Bing Wan,Xi Chen,Ping Zhan,Ping Zhan,Ping Zhan,Yuan Zhao,Tianli Zhang,Hongbing Liu,Hongbing Liu,Hongbing Liu,Muhammad Zubair Afzal,Said Dermime,Steven N. Hochwald,Paul Hofman,Hossein Borghaei,Dang Lin,Tangfeng Lv,Tangfeng Lv,Tangfeng Lv,Yong Song,Yong Song,Yong Song +22 more
TL;DR: PD-L1 expression may be a valuable predictor of the efficacy of anti-PD-1/PD- L1 monotherapy in certain NSCLC patients, however, the combination of chemotherapy plus immunotherapy significantly improved survival regardless of the PD-L 1 expression level in the first-line treatment of NSClC.